DiscoverKFF's The Business of Health with Chip Kahn
KFF's The Business of Health with Chip Kahn
Claim Ownership

KFF's The Business of Health with Chip Kahn

Author: KFF

Subscribed: 8Played: 84
Share

Description

This weekly podcast features insightful conversations between host Chip Kahn and his guests, who discuss the business of health care, connecting the dots between the health care business, policy, and patients.

Hosted on Acast. See acast.com/privacy for more information.

25 Episodes
Reverse
AI is speeding up the search for new medicines. Can it make the discoveries themselves?Few people are better placed to answer than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don’t exist in nature, and he is now vice chairman and president of its parent company, OPKO Health.His test for AI: give it every piece of data available in the early 1950s, and it would not have found the double helix. The spark, he argues, is still human.Chip and Dr. Zerhouni dig into what AI is actually doing in drug development, how the FDA stacks up against regulators abroad, and what a slowdown in AI — and the erosion of American research — could mean for the next generation of cures. Hosted on Acast. See acast.com/privacy for more information.
Most hospitals buy their AI. Charité – Universitätsmedizin Berlin, Europe’s largest academic medical center and ranked eighth in the world by Newsweek, is developing its own. Charité has consolidated its scattered AI projects into a single Institute for Artificial Intelligence in Medicine and switched on Clé, an in-house platform that runs across research, teaching, patient care, and administration. Its success, says Chief Executive Officer Prof. Dr. Heyo Kroemer, will depend on whether it improves care, supports staff, and makes innovation usable in everyday work. In this episode, Chip and Kroemer talk about what Charité stands to gain or lose by taking this path, and what it means to own an AI platform rather than license one. Hosted on Acast. See acast.com/privacy for more information.
Can AI Find the Cure?

Can AI Find the Cure?

2026-10-2741:11

Medicine has its maps: Anatomists charted the body, and the Human Genome Project gave us the code. Now, the Human Cell Atlas, a global effort involving thousands of scientists, is using AI to create comprehensive reference maps of all human cells to understand human health and diagnose, monitor and treat disease. Given the extraordinary implications for drug discovery and potential cures, Chip talks with Dr. Sarah Teichmann, co-founder of the Human Cell Atlas, chair in Stem Cell Medicine at the University of Cambridge, and a non-executive director at 10x Genomics, among other roles, about the potential of the Human Cell Atlas. Hosted on Acast. See acast.com/privacy for more information.
Walk into the emergency room at Israel’s largest hospital and the first clinician to take your history may be an AI avatar — with a physician signing off on every recommendation. Israel’s Sheba Medical Center is building what could become the first fully AI-based hospital by 2030. Dr. Eyal Zimlichman, Sheba's Chief Transformation Officer, Chief Innovation Officer and Chief AI officer, talks with Chip about what that means for patients. During their conversation, Dr. Zimlichman argues that in the future, doctors will "be much more humane than the doctors of the present...because if we're not able to achieve that, then there's really no difference between the AI and the physician...we will be able to compete with the AI in terms of humanity." Hosted on Acast. See acast.com/privacy for more information.
Health care's AI future is being built right now. The open question is “for whom?” Dr. Uché Blackstock — emergency physician, former associate professor at NYU School of Medicine, founder and CEO of Advancing Health Equity, and author of The New York Times bestseller “Legacy: A Black Physician Reckons with Racism in Medicine” — joins host Chip Kahn to argue that AI governance should be shaped not only by regulators and review boards, but by the communities the tools are meant to serve. Dr. Blackstock explains why she is skeptical of technology that presents itself as neutral, how average performance can conceal unequal harm, and what equitable AI design would require. She also makes the business case for equity and describes trust as infrastructure that can be designed into the system. Will the AI revolution reach the patients American health care has historically failed — or pass them by? Hosted on Acast. See acast.com/privacy for more information.
loading
Comments